Sales of Celgene’s marquee cancer drug surge as Trump’s price-crackdown looms

Published



Sales of Celgene’s marquee cancer drug are growing despite questions about how the Trump administration’s plan to address rising drug costs will affect pharmacy companies.

[Trump speech on drug prices set for May 11, sources say]

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.